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MEDI-534  is  the  ﬁrst  live,  attenuated  and  vectored  respiratory  syncytial  virus  (RSV)  vaccine  to  be evalu-
ated in  seronegative  children.  It consists  of  a  bovine/human  parainﬂuenza  virus  type  3 (PIV3)  backbone
with  the  RSV fusion  glycoprotein  (RSV-F)  expressed  from  the  second  position.  The  PIV3  fusion  and
hemaglutinin-neuraminidase  proteins  are  human-derived.  No  small  animal  appropriately  replicates  the
restrictive  growth  of  bovine  PIV3  (bPIV3)  based  viruses  relative  to  human  PIV3  (hPIV3)  observed  in  the
respiratory  tract  of  rhesus  monkeys  and  humans,  making  analysis  of  the  genetic  stability  of the  attenua-
tion phenotype  and  maintenance  of RSV-F  expression  difﬁcult.  Screening  of  multiple  cell-lines  identiﬁed
MRC-5 cells  as  supporting  permissive  growth  of  hPIV3  while  restricting  bPIV3  and  MEDI-534  growth.  In
MRC-5  cells,  the  peak  titers  of  MEDI-534  were  more  than  20-fold  lower  compared  to  hPIV3  peak  titers.
After  more  than  10 multicycle  passages  in  MRC-5  cells,  genetic  alterations  were  detected  in  MEDI-534
that  contributed  to  a partial  loss  in restricted  growth  in  MRC-5  cells  and  a  decrease  in RSV-F  expression.
These  adaptive  mutations  did  not  occur  in the  RSV-F  gene  but  were  found  in  the  polyA  sequence  upstream
of  the  transgene.  MRC-5  adapted  MEDI-534  viruses  (1)  lost  some  attenuation  but  did  not  replicate  to  the
level  of  hPIV3  in  this  cell  line,  (2)  did not  completely  lose  RSV-F  expression  and  (3)  were  able to elicit a
protective anti-RSV  immune  response  in  hamsters  despite  lower  levels  of RSV-F  expression.  Interestingly
analysis  of  shed  MEDI-534  from  a  recent  clinical  trial  indicates  that in some  recipients  similar  mutations
arise  by  day  7  or  day  12  post  immunization  (in  press)  suggesting  that  these  mutations  can  arise rapidly
in the  human  host.  The  utility  and  limits  of  MRC-5  cells  for characterizing  the  attenuation  and  RSV-F
s  disc
e Auexpression  of  MEDI-534  i
© 2013 Th
. Introduction
Multiple approaches to pediatric respiratory syncytial virus
RSV) vaccination have been evaluated in the clinic over the past 30
ears, but to date there are no licensed RSV vaccines [1]. MEDI-534,
he most clinically advanced live pediatric RSV vaccine candidate
2], is a chimeric bovine/human parainﬂuenza virus type 3 (PIV3)
hat expresses the RSV-F antigen (Fig. 1A). All internal genes are
erived from bPIV3 but the bovine F and HN surface glycoproteins
re substituted with analogs from hPIV3 [3,4], making MEDI-534 a
otential bivalent vaccine against RSV and hPIV3.
∗ Corresponding author. Tel.: +1 650 603 2348; fax: +1 650 603 3348.
E-mail addresses: nelsonc@medimmune.com (C.L. Nelson),
angr@medimmune.com (R.S. Tang), elizabeth stillman@yahoo.com,
awlorh@medimmune.com (E.A. Stillman).
264-410X     ©  2013 The Authors. Published by Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.vaccine.2013.04.015
Open access under CC BY-ussed.
thors. Published by Elsevier Ltd. 
For a safe and effective RSV vaccine, two key characteristics are
required for MEDI-534: (1) maintenance of attenuation phenotype
and (2) maintenance of RSV-F expression. Since host range restric-
tion of MEDI-534 is polygenic and attributed to multiple bPIV3
genes [5], a complete reversion to hPIV3 virulence is unlikely. Inser-
tion of the extra RSV-F transcriptional unit likely also contributes
to the attenuation phenotype in humans. Since RSV-F expression
is not essential for MEDI-534 replication, there is potential to lose
its expression during replication under host-range restricted con-
ditions such as the human respiratory tract. It is known that RSV-F
expression is stable following multiple passages of MEDI-534 in
permissive cell lines such as VEROs and in lungs of permissive
animals such as hamsters (unpublished data). However, these bio-
logical systems do not effectively model the host range restriction
of bPIV3-based vaccines observed in the respiratory tract of rhe-
sus monkeys and young children [6,7], and up until this point no
Open access under CC BY-NC-ND license. small animal model or cell line had been identiﬁed for pressure
testing the phenotypic stability of MEDI-534 attenuation and RSV-
F expression. Here we  demonstrate that bPIV3 based viruses, unlike
hPIV3, are attenuated for replication in the MRC-5 human lung cell
NC-ND license. 
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aig. 1. Growth characteristics of PIV3 based viruses. Schematic diagram of MEDI-5
re  shown in white and human PIV3 genes are shown in dark gray. Multicycle grow
ith  the titer for each timepoint determined in quadruplicate. The limit of detectio
ine. After multiple passages in this bPIV3 host range restricted sys-
em, changes occurred in the upstream polyadenylation signal that
educed RSV-F expression and increased peak replication titers.
A recent Phase 1 study demonstrated that MEDI-534 is safe and
mmunogenic in healthy RSV and PIV3 seronegative children 6 to
24 months of age [2]. Analysis of shed MEDI-534 viruses from
he Phase 1 study identiﬁed the presence of variant subpopula-
ions with altered RSV-F expression caused by similar mutations
escribed in this current study (in press), validating the utility of
he MRC-5 in vitro model to assess the stability of vectored vaccines
rior to clinical trials.
. Materials and methods
.1. Viruses and cells
MEDI-534 was grown in VERO cells and puriﬁed by tangential
ow ﬁltration [8]. All other viral stocks were generated as previ-
usly described and titered by plaque assay [4,9].
VERO cells were maintained as described previously [4]. MRC-
 cells (passages 19-29; ATCC#CCL-171) were maintained at
7 ◦C in DMEM supplemented with 10% FBS (Hyclone), 0.1% gen-
amicin (Gibco), 1% l-glutamine (JRH), and 1% sodium pyruvate
Hyclone).
.2. Generation of viral cDNA and recombinant viruses
MEDI-534 and its derivatives were engineered and propagated
s previously described [4]. For MEDI-534 F-stop, oligonucleotides
ere designed to convert the starting methionine to a threonine
nd the 2nd and 28th amino acid to a stop codon using QuikChange
Stratagene). NpolyA virus contains the a1699g mutation in the
IV3-N polyadenylation sequence present in lineages 23A and 23C.
 ORF virus contains the S74G amino acid change in the PIV3-M
pen reading frame (nucleotide change a5862g). The N/M virus
ontains both mutations, introduced by oligonucleotides (Strata-
ene QuikChange 2XL). Full-length clones were generated using
he 1-5 bPIV3 plasmid subclone and b/hPIV3 genome [9].
Recombinant viruses were generated by transfection of full-
ength cDNA together with expression plasmids pCite PIV3-N, P
nd L [3] in BSR-T7 cells as previously described [10]. The RSV F gene (light gray) is in position 2 of the PIV3 genome. Bovine PIV3 genes
rves in VERO cells (B) or MRC-5 cells (C). Shown are representative growth curves
dicated by dotted lines. Error bars indicate SEM.
2.3. Serial passaging of MEDI-534
In three separate infections, MRC-5 cells at 100% conﬂuency
were infected with MEDI-534 at an m.o.i. of 0.001. Supernatants
were harvested on day 3 post-infection. Virus was stabilized by
addition of 10× SPG (10× is 2.18 M sucrose, 0.038 M KH2PO4,
0.072 M K2HPO4, 0.054 M l-glutamate, pH 7.1) prior to freezing at
−80 ◦C. For passages 2-23, an estimated peak titer of ∼4.5 log10
TCID50/ml for each prior passage day 3 harvest was used to calculate
a starting infection m.o.i. of 0.001. Characteristic cytopathic effect
was  used to conﬁrm the presence of MEDI-534 during passaging.
Three separate lineages were maintained in parallel throughout the
passaging.
2.4. Growth curves
VERO or MRC-5 monolayers were infected at an m.o.i. of 0.001
and incubated at 37 ◦C (VERO) or 33 ◦C (MRC-5) in 5% CO2 incu-
bators. At indicated time points, supernatants were harvested
and stabilized with 1× SPG for storage at −80 ◦C. Growth curve
titers were determined by TCID50 [4] in VERO cells. Statistical
analysis was  by ANOVA, with a Tukey adjustment for pairwise
comparisons.
2.5. Western and northern blot
Cell lysates were analyzed by standard western blot. Brieﬂy,
VERO cells were infected at an m.o.i. of 0.001 with the indicated
viruses and harvested on day 3 post-infection. Western blots were
probed with an anti-RSV-F MAb  (MedImmune) at a 1:1000 to 1:20K
dilution or a rabbit anti-PIV3-N polyclonal antibody (#181, Med-
Immune) at a 1:40K dilution, followed by HRP conjugated rabbit
anti-human IgG or goat anti-rabbit IgG antibody at a 1:2000 to a
1:20K dilution (DAKO). Protein-antibody complexes were visual-
ized by chemiluminescence (ECL-plus, Amersham).
For northern blot analysis, VERO cells were infected at an m.o.i.
of 0.001. At 3 days post-infection total RNA was  isolated using the
QIAGEN RNeasy kit, fractionated on a 1% agarose gel using gly-
oxal (Ambion) and transferred to a nylon membrane (Schleicher &
Schuell). Blots were hybridized with genomic sense transcription-
ally labeled (Digoxygen-UTP, Roche) ssRNA probes against RSV-F
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r PIV3-N for detection of mRNA species. Probe-RNA complexes
ere visualized by chemiluminescence (Roche). Approximately
00 bases of RSV-F and PIV3-N negative-sense RNA probes were
ranscribed (Roche) from pSPT18 plasmids containing these genes
ontrolled by the SP6 RNA polymerase promoter.
.6. Sequence analysis
MEDI-534 P23 viruses were sequenced from nucleotides 62 to
7,280. Sections of 600-2700 kb were ampliﬁed by RT-PCR (Invit-
ogen) from virus stocks and sequenced by Sequetech (Mountain
iew, CA).
.7. Hamster study
Six- to eight-week-old Syrian Golden hamsters were dosed
ntranasally with 104 p.f.u. of the indicated viruses. On day
8, Group A hamsters (n = 5) were challenged intranasally with
06 p.f.u. RSV/A2 and Group B hamsters (n = 5) were boosted
ntranasally with 106 p.f.u. MEDI-534. Four days post-challenge,
roup A hamsters were euthanized with CO2 and lungs were
itered for RSV as described previously [4]. Group B hamsters
ere anesthestized with isoﬂuorane and bled on days 28 and
6. Neutralizing antibody titers were determined as described
reviously [2] and total IgG antibody titers were determined by
tandard ELISA. Two hundred ng/well of soluble RSV-F was used
s the coating antigen. A 1:5000 dilution of goat anti-hamster-
RP (KPL) was used as the detection antibody. All procedures
ere performed in accordance with federal, state and insti-
utional guidelines in an AAALAC-accredited facility and were
pproved by the MedImmune Institutional Animal Care and Use
ommittee.
. Results
.1. Demonstration of restricted bPIV3 replication in MRC-5 cells
In VERO cells, the vaccine production cell line, replication of
EDI-534, hPIV3, and bPIV3 was fully permissive, with peak titers
anging from 8.1 to 8.6 log10 TCID50/ml  (Fig. 1B). b/hPIV3, a chimeric
ovine/human PIV3 with hPIV3 fusion and hemagglutinin genes,
ut without the additional RSV-F transcriptional unit, also repli-
ated to peak titers within this range. These data and earlier data
4,11] conﬁrmed that there are no gross incompatibilities gener-
ted by the substituted hPIV3 F and HN genes or by the insertion of
he RSV-F transgene.
In MRC-5 cells (Fig. 1C), hPIV3 replication was  fully permis-
ive, achieving peak titers of 8.2 log10 TCID50/ml. However, bPIV3
eplication was restricted, peaking at 5.5 log10 TCID50/ml. b/hPIV3
eak titers were similar to hPIV3 suggesting that bovine F and HN
enes are major determinants of the bPIV3 restricted growth phe-
otype in MRC-5 cells (Fig. 1C). With MEDI-534, insertion of RSV-F
nto the b/hPIV3 backbone was restrictive, lowering peak titers by
1.5 log10 TCID50/ml relative to hPIV3. Insertion of the transcrip-
ional unit, not RSV-F protein expression, was responsible for the
estricted growth. MEDI-534 with stop codons introduced into the
SV-F ORF (MEDI-534 F-stop) was also equally restricted for repli-
ation in MRC-5 cells. Importantly, the replication trends of hPIV3,
PIV3 and MEDI-534 in MRC-5 cells recapitulate that observed in
he respiratory tract of rhesus monkeys [6 and unpublished data],
uggesting that MRC-5 cells may  be a relevant system for studying
EDI-534 attenuation and maintenance of RSV-F expression under
estrictive growth.1 (2013) 3756– 3762
3.2. Partial loss of restricted replication and RSV-F expression
upon high passage of MEDI-534 in MRC-5 cells
To evaluate the maintenance of the MEDI-534 restricted repli-
cation as well as RSV-F gene expression under selective growth,
3 independent infections of MEDI-534 were serially passaged 23
times in MRC-5 cells at an m.o.i. of 0.001. Three separate lineages
were maintained during this passaging, denoted as P23A, P23B, and
P23C.
Multicycle growth curves in MRC-5 and VERO cells were gen-
erated for each lineage at passage 10 (P10) and passage 23
(P23). As expected, all viruses grew to high titers in VERO cells
(data not shown). However, at passage 23, all three lineages had
higher peak titers in MRC-5 cells compared to P10 and MEDI-534
(Fig. 2A). By passage 23, the average day 4 titers for all three lin-
eages were statistically higher than MEDI-534 (Fig. 2B). Western
blot analysis indicated that P23 viruses also had reduced RSV-
F protein expression (Fig. 3A). Reduction in protein expression
was  accompanied by an increase in transcription read-through
at the N-RSV-F gene junction (Fig. 3B and C). Therefore, a reduc-
tion in RSV-F expression and an enhancement in replication
were observed for MEDI-534 at high passages in a restrictive
cell line.
3.3. Identiﬁcation of mutations in high passage MEDI-534
Complete genome sequencing was performed on the three P23
lineages (Fig. 4). No point mutations and/or deletions in the RSV-F
ORF were detected. This result was  unexpected because (1) RNA-
dependent RNA polymerases are error prone and (2) the RSV-F
ORF is not essential for MEDI-534 propagation. Three categories of
nucleotide changes were identiﬁed. (1) An identical point muta-
tion found in all three lineages in the bPIV3-M ORF resulted in
a serine to glycine change at amino acid 74. This change was
detected at P10 when no growth enhancement was observed (data
not shown). Therefore, this mutation likely does not contribute to
the down-regulation of RSV-F protein expression or the enhance-
ment of MEDI-534 replication in MRC-5 cells. (2) Mutations in the
semi-conserved bPIV3-N gene end/polyadenylation signal. Poly-
morphisms were observed at nt1699 and/or nt1701, where an A
was  changed to a G or C (3′-AGUAAGAAA1699AA1701-5′). Lineage
A had changes at both nucleotides (A1699C and A1701C), while
lineages B and C had single nucleotide changes at A1701C and
A1699G, respectively. These mutations were not detected at P10.
(3) Three point mutations in hPIV3-HN and bPIV3-L that were
not consistently present in all lineages. These mutations were not
investigated further.
3.4. Role of acquired mutations
To investigate the role of the acquired mutations, A1699G
(NpolyA), and the bPIV3-M mutation, S74G (M ORF), were intro-
duced either separately or in combination (N/M) into the MEDI-534
genome. As expected, all viruses replicated permissively in VERO
cells with peak titers ≥7.9 log10 TCID50/ml  (data not shown). How-
ever, in MRC-5 cells, peak titers of the NpolyA mutant and the
N/M mutant were signiﬁcantly higher than MEDI-534 (p < 0.001)
while titers for the M ORF mutant were not signiﬁcantly different
from MEDI-534 (Fig. 5A), suggesting that the 1 log loss of atten-
uation results from the NpolyA mutation. Western blot (Fig. 5B)
and northern blot analysis (Fig. 5C and D) conﬁrmed that the
NpolyA mutation increased N-RSV-F read-through transcription
and reduced RSV-F expression. The role of the M gene mutation
was  not determined.
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Fig. 2. MRC-5 adapted MEDI-534 viruses. Representative multicycle growth curves in MRC-5 cells (A). The limit of detection is indicated by a dotted line. The TCID50 analysis
was  run in quadruplicate for each sample. Error bars indicate SEM. (B) Shown is the average titer at 4 days post infection from 5 individual infections. Error bars indicate
SEM.  ANOVA and Tukey adjustment were used for pairwise comparisons between groups. The TCID50 analysis was run in quadruplicate for each sample.
Fig. 3. RSV-F expression from MRC-5 adapted MEDI-534 viruses. (A) Western blot analysis. VERO cell lysates were probed with anti-RSV-F monoclonal antibody (top panel)
or  anti-PIV3 polyclonal antibody (bottom panel). The PIV3-N signal served as a replication control. The arrows indicate positions of bands corresponding to the predicted
sizes  of full-length precursor RSV-F (F0) and cleavage fragment RSV-F (F1). Shown is a representative blot from multiple independent experiments. Commercially prepared
protein  ladder (Invitrogen SeeBlue Plus2, sizes in kDa). (B) Northern blot analysis on total RNA from MRC-5 infected cells. Blots were probed with an 800 bp PIV3-N speciﬁc
anti-sense RNA probe, or (C) an 800 bp RSV-F speciﬁc anti-sense RNA probe. Commercially prepared RNA marker (Ambion BrightStar Biotinylated RNA Millenium markers,
sizes  in kb).
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Fig. 4. Diagram of nucleotide and amino acid changes in MRC-5 adapted MED
.5. Effect of reduced RSV-F expression on immunogenicity and
rotection in hamsters
To determine the impact of reduced expression on RSV immuno-
enicity, Syrian golden hamsters, which are fully permissive for
ig. 5. Effect of mutations on attenuation and RSV-F expression. (A) MRC-5 cells were infec
he  average titer from 5 individual infections with the standard deviation. The TCID50 anal
sed  for pairwise comparisons between groups. (B) Western blot analysis on virus infec
upper  panel) or anti-PIV3-N polyclonal antibody (lower panel). The PIV3-N signal serve
as  reduced to 1/10, compared to the remaining samples. The arrows indicate positions
nd  cleavage fragment RSV (F1). Commercially prepared protein ladder (Invitrogen SeeB
xperiments. (C) Northern blot analysis on total RNA from MRC-5 infected cells. Blots we
SV-F  speciﬁc anti-sense RNA probe. Commercially prepared RNA marker (Ambion Brigh5’
iruses. Adapted viruses at P23 were sequenced from nucleotide 62 to 17,280.
replication of bPIV3 and hPIV3, were immunized intranasally with
104 p.f.u of the viruses indicated in Table 1, and a subset were
challenged on day 28 with 106 p.f.u. RSV/A2. Hamsters immunized
with MEDI-534 or NpolyA were protected from RSV/A2 challenge,
with lung RSV titers ≤0.8 log10 p.f.u./g tissue. As expected, groups
ted with the indicated viruses at an m.o.i. of 0.001 and harvested on day 5. Shown is
ysis was  run in quadruplicate for each sample. ANOVA and Tukey adjustment were
ted VERO cell lysates. Blots were probed with an anti-RSV-F monoclonal antibody
d as a replication control. The amount of lysate loaded for MEDI-534 and M ORF
 of bands corresponding to the predicted sizes of full-length precursor RSV-F (F0)
lue Plus2, sizes in kDa); shown is a representative blot from multiple independent
re probed with an 800 bp PIV3-N speciﬁc anti-sense RNA probe and (D) an 800 bp
tStar Biotinylated RNA Millenium markers, sizes in kb).
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big. 6. Effect of reduced RSV-F expression on immunogenicity. (A) Neutralizing anti
B)  Total RSV-F IgG antibody titers were measured by ELISA. Error bars represent SD
mmunized with b/hPIV3 or placebo displayed mean RSV titers
1.9 log10 p.f.u./g tissue in lungs and were not protected (Table 1).
t 28 days post immunization, only MEDI-534 immunized animals
how detectable RSV neutralizing antibody titers (Fig. 6A). How-
ver, NpolyA immunized animals elicited an anti-F IgG response
Fig. 6B), indicating exposure to RSV-F, and were protected from
SV challenge in the lungs (Table 1). Therefore the reduced lev-
ls of F expression resulted in lower RSV neutralizing antibody
iters but did not reduce the level of protection in this animal
odel.
Subjects in the Phase 1 clinical trial received 3 doses of MEDI-
34 at 2-month intervals [2]. Therefore it is of interest to determine
hether the immune response to RSV-F can be boosted by a
econd dose of MEDI-534 in the presence of immunity to the
IV3 vector. Remaining hamsters were boosted intranasally with
06 p.f.u. MEDI-534 on day 28. RSV neutralizing antibody titers
ost MEDI-534 boost were signiﬁcantly increased for both NpolyA
nd MEDI-534 immunized hamsters (Fig. 6A) showing that ani-
als primed with RSV-F could be boosted in the presence of
ector immunity. In the absence of RSV-F priming (b/hPIV3 immu-
ization), no boosting in RSV neutralization titers were observed
lthough a low level of RSV-F IgG was detected (Fig. 6B). These
ata suggest that NpolyA immunized animals were primed with
he RSV-F antigen even though the level of expression was reduced,
nd the low neutralizing RSV-F titer was signiﬁcantly boosted by
EDI-534.
able 1
PolyA and MEDI-534 protect Syrian golden hamsters from challenge with RSV/A2.
Immunizing virus n Mean virus titer post-challenge
(log10 p.f.u./g tissue) ± SD
Placebo 10 2.5 ± 1.6
MEDI-534 5 0.4* ± 0.1
N-PolyA 5 0.5* ± 0.4
b/h PIV3 5 1.8 ± 1.4
roups of hamsters were inoculated with placebo medium or 104 p.f.u. of the listed
irus on day 0. On day 28, hamsters were challenged with 106 p.f.u. RSV/A2. Four days
ost-challenge, lungs were harvested and titered. For animals with undetectable
ung titers the average LOD/2 (0.4 p.f.u./g) was used for mean and standard deviation
alculations. Data shown represents one study of two.
* p-Value = 0.02 for MEDI-534 vs placebo and p-value = 0.02 for N-polyA vs placebo
y  one-sided non-parametric Wilcoxon rank sum test.iters against RSV/A2-GFP on days 28 and 56. Dotted line indicates limit of detection.
4. Discussion
MRC-5 cells provided an in vitro system to pressure test the
maintenance of the attenuation phenotype following MEDI-534
replication under bPIV3 restrictive growth conditions. Previously,
this type of in vitro analysis had been hampered by the lack of cell
lines or small animals that could mimic  the host range restricted
growth of bPIV3 observed in humans and rhesus monkeys [6,7].
The intermediate restricted growth of MEDI-534 was stable for ≥10
passages in MRC-5 cells. However, further passaging resulted in
adaptive mutations in three independent lineages that mapped to
the bPIV3-N polyadenylation signal, leading to partial loss of the
restrictive growth phenotype with concomitant reduction of RSV-
F expression. The fact that (1) no other changes found in any bPIV3
genes reduced the attenuation phenotype, (2) no viral population
had a complete loss of F expression (data not shown), and (3) MRC-
5 adapted MEDI-534 never attained replication levels observed for
pathogenic hPIV3 points to the overall genetic stability of this vac-
cine candidate under restricted growth.
The other mutation common to all lineages of MRC-5 adapted
viruses is the S74G change in the bPIV3M ORF. The PIV3-M protein
is essential for the formation of virion structure, playing a direct
role in the budding process [12,13]. However, this mutation did not
contribute to the reduction in attenuation of MEDI-534 in MRC-
5 cells or RSV-F down-regulation. The signiﬁcance of this change
is currently unknown and beyond the scope of this study. The
nucleotide polymorphisms found within the PIV3-N polyadenyla-
tion sequence caused read-through of the bPIV3-N and RSV-F gene
junction, thereby reducing the level of RSV-F protein expression.
The effect of this type of mutation is well documented in other non-
segmented negative strand viruses such as VSV and RSV [14–20].
These types of mutations prevent the polymerase from polyadeny-
lating the viral transcript, a prerequisite for transcript termination
of the upstream gene and re-initiation at the downstream gene.
The upstream polyA tract can be a hot-spot for selective mutations,
particularly when the inserted sequence is toxic to the virus lifecy-
cle [19–21]. RSV-F expression was  not toxic in MEDI-534 (Fig. 2C,
MEDI-534 vs MEDI-534stop) but its transcription contributed to
the attenuation phenotype; therefore, it was not unexpected to ﬁnd
mutations in the polyA region that increased viral ﬁtness. Negative
strand viruses have a transcriptional gradient in which transcrip-
tion for each downstream gene is progressively decreased [22]. For
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EDI-534, insertion of RSV-F likely disrupts this gradient. While
 change in the transcriptional gradient was not obvious in the
orthern blot analyses, a move toward restoration of the original
PIV3 transcriptional gradient could explain selection of NpolyA
utations.
Normal Human Bronchial Epithelial (NHBE) cells also support
he differential growth of hPIV3, bPIV3 and MEDI-534 (data not
hown). Based on our hypothesis that the NpolyA mutations moved
o restore the transcriptional gradient, similar adaptive changes
ould likely occur in NHBE cells. Currently we do not understand
he biological mechanism that contributes to the restrictive growth
f bPIV3 in MRC-5 or NHBE cells. bPIV3 may  grow more poorly in
hese human cells because it has not evolved to counteract human
ntiviral responses.
MEDI-534 with reduced RSV-F expression elicited a reduced,
ut protective anti-RSV immune response. Importantly, this RSV-
 response could be boosted in the presence of bPIV3 vector
mmunity by a second immunization with unaltered MEDI-534,
uggesting that the reduced amount of RSV-F provided sufﬁcient
riming for a boost in hamsters. This priming may  be relevant in a
linical setting where multiple doses of MEDI-534 are administered
2].
Replacing the bPIV3-F and HN genes with hPIV3 analogs
estored its growth to hPIV3 levels. However, b/hPIV3 had an
cceptable safety proﬁle in PIV3 seronegative children [7]. Thus
his MRC-5 system has limited utility for predicting the safety of
himeric PIV3 viruses because of the lack of correlation between
/hPIV3 replication in MRC-5 cells and safety in children. In the
ecent Phase 1 trial [2], sequence analysis of shed MEDI-534 viruses
dentiﬁed variants with similar NpolyA adaptive changes that arose
y day 7 or day 12 post immunization (in press) suggesting that
hese mutations can arise quickly in the human host. These recent
linical data validate the use of MRC-5 cells to evaluate the main-
enance of both RSV-F expression and the attenuation phenotype
nder bPIV3 restricted conditions. MRC-5 cells may  also be a useful
urrogate system for development of a phenotype assay to conﬁrm
he attenuation phenotype of MEDI-534 vaccine lots and to char-
cterize the attenuation phenotype of shed viruses from clinical
rials.
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